Drug
Axs 02
Axs 02: highest development phase Phase 3, developed by Axsome Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Axsome Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| AXS-02 NCT02746068 | Phase 3 | Osteoarthritis, Knee |
| AXS-02 (oral zoledronate) NCT02504008 | Phase 3 | Complex Regional Pain Syndrome |
Latest
No recent events.
Follow Axs 02 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.